Clinical pharmacology of intracarotid etoposide.

Pharmacokinetics studies were performed in ten patients who received VP-16 by intracarotid infusion at 100-300 mg/m2. VP-16 was analyzed by high-pressure liquid chromatography. ESTRIP and NONLIN were used to characterize VP-16 pharmacokinetics. VP-16 disappeared biphasically, with a t1/2 beta of 6.1 +/- 1.4 h; the total clearance was 26.8 +/- 2.8 ml/min/m2, and the Vss was 8.8 +/- 1.6 l/m2. The pharmacokinetics was not significantly different after administration by the IV route. However, at a lower dosage, less than 140 mg/m2, the half-life appears to be shorter. This may or may not be significant, since VP-16 pharmacokinetics is quite variable and the number of patients studied is relatively small. Overall, the brain and brain tumor do not appear to have any first-pass effect on VP-16 pharmacokinetics.